Rheumatoid arthritis patients who fail on a first-time trial of tumor necrosis factor inhibitor therapy should change to a biologic with a different mechanism of action, explains Dr. Daniel E. Furst.
Video
When Rheumatoid Arthritis Biologics Fail
